Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rezvilutamide neoadjuvant therapy with ADT with or without docetaxel for oligometastatic hormone-sensitive prostate cancer
ChiCTR2400093262Phase 4Recruiting
- Sponsor
- The First Affiliated Hospital of Wenzhou Medical University
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of rezvilutamide in prostate cancer (PCa) (2 arms), sponsored by The First Affiliated Hospital of Wenzhou Medical University. Primary endpoint: Pathologic complete response rate. Started Nov 2024; status: recruiting.
02
Drugs
rezvilutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on ChiCTR2400093262.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400093262.